Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04233073 · ClinicalTrials.gov registry record · Phase 2
Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery
A Phase 2 study, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04233073 is a Phase 2 study that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 10 participants.
The verdict
NCT04233073, a Phase 2 study, was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
Prospective, open-label clinical trial to evaluate the efficacy and safety of andexanet alfa patients who require urgent surgery that have been anticoagulated with the FXa (activated factor X) inhibitors.
Interventions
- DRUG andexanet alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-06-27 |
| Est. Completion | 2022-01-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04233073
The ClinicalTrials.gov registry entry for NCT04233073 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which andexanet alfa is the first listed.
NCT04233073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04233073 about?
NCT04233073 is a clinical study titled "Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery". Prospective, open-label clinical trial to evaluate the efficacy and safety of andexanet alfa patients who require urgent surgery that have been anticoagulated with the FXa (activated factor X) inhibitors.
What is the current status of trial NCT04233073?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2021-06-27. Estimated completion is 2022-01-25.
What interventions are being tested in trial NCT04233073?
The interventions under investigation include: andexanet alfa (DRUG).
Who is sponsoring clinical trial NCT04233073?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.